- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Toshiba unveils JustVision scanners
Japanese ultrasound developer Toshiba unveiled a new line of compact scanners at last month's International Congress of Radiology meeting in New Delhi, India. The line consists of JustVision 200, a hand-carried unit that weighs just 16 kg, and JustVision
Japanese ultrasound developer Toshiba unveiled a new line of compact scanners at last month's International Congress of Radiology meeting in New Delhi, India. The line consists of JustVision 200, a hand-carried unit that weighs just 16 kg, and JustVision 400, a cart-mounted system with a larger monitor.
Both JustVision systems are convex and linear scanners that include transducers that support abdominal, ob/gyn, intraoperative, superficial, and cardiovascular applications. In addition, JustVision transducers can be switched between three different frequencies depending on the depth of the region of interest. The feature enables sonographers to use one probe for exams that might otherwise require three scanheads.
Toshiba plans to roll out the JustVision line internationally this month. The company will begin marketing the systems in the U.S. in early 1999, according to a spokesperson with the vendor's U.S. subsidiary, Toshiba America Medical Systems in Tustin, CA.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
